Finance

Lists
Q3 2026 earnings • released • EPS miss -52.73%
See results
MBX:NASDAQ
MBX Biosciences Inc
$55.94
+2.62%
(+1.43) 1D
$55.94
0.00% (0.00)
After hours
Closed: Nov 13, 4:00:00 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for MBX...
Open
$54.49
High
$57.11
Low
$52.94
Mkt. cap
2.78B
Avg. vol.
565.64K
Volume
855.45K
52-wk high
$72.64
52-wk low
$23.07
EPS
-$3.06
Shares outstanding
49.66M
No. of employees
63
Open
$54.49
High
$57.11
Low
$52.94
Mkt. cap
2.78B
Avg. vol.
565.64K
Volume
855.45K
52-wk high
$72.64
52-wk low
$23.07
EPS
-$3.06
Shares outstanding
49.66M
No. of employees
63
News stories
From web sources and news partners
About MBX Biosciences Inc
CEO-
Employees63
Founded2018
HeadquartersCarmel, Indiana, United States
SectorHealth Care
IndustryPharmaceutical industry
Websitembxbio.com
Analyst ratings
Based on 7 analysts giving stock ratings to MBX in the past 3 months
Strong buy
Buy
7
Hold
0
Sell
0
12-month forecast
Based on 7 Wall Street analysts offering 12 month price targets for MBX in the last 3 months.
Highest
Current $55.94
$150.00 (+168.14%)
Average
$95.71 (+71.09%)
Lowest
$80.00 (+43.01%)
Analyst
Recommendation
Action
Price target
Projected
Date
Mitchell Kapoor
H.C. Wainwright
Buy
Initiated
$90.00
+60.9%
11/12/2026
Unknown Analyst
Oppenheimer
Buy
Reiterated
$80.00
+43%
11/11/2026
Michael Yee
UBS
Buy
Maintained
$90.00
+60.9%
11/10/2026
Annabel Samimy
Stifel Nicolaus
Buy
Maintained
$84.00
+50.2%
11/10/2026
Eliana Merle
Barclays
Buy
Maintained
$88.00
+57.3%
10/13/2026
Seamus Fernandez
Guggenheim
Buy
Reiterated
$150.00
+168.1%
10/12/2026
Jessica Fye
J.P. Morgan
Buy
Initiated
$88.00
+57.3%
08/21/2026
Srikripa Devarakonda
Truist Financial
Buy
Maintained
$88.00
+57.3%
08/10/2026
Uy Ear
Mizuho Securities
Buy
Reiterated
$91.00
+62.7%
08/07/2026
Patrick Dolezal
LifeSci Capital
Buy
Reiterated
$121.00
+116.3%
08/08/2026
Jonathan Wolleben
Citizens JMP
Buy
Maintained
$86.00
+53.7%
05/12/2026
Patrick Scholes
Truist Financial
Buy
Maintained
$70.00
+25.1%
05/11/2026
Tyler Van Buren
TD Cowen
Buy
Maintained
-
-
05/07/2026
Last report
Nov 9, 2026
Fiscal period
Q3 2026
-$1.29 / -$0.84
-52.73%miss
Revenue / Est. (USD)
- / 0.00
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
19.46M
18.47M
30.98M
32.05M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
6.34M
8.79M
9.95M
34.30M
Operating expense
25.80M
27.26M
40.93M
66.34M
Total operating expenses
25.80M
27.26M
40.93M
66.34M
Operating income
-25.80M
-27.26M
-40.93M
-66.34M
Other non operating income
-
-
-
-
EBT including unusual items
-22.06M
-23.52M
-37.10M
-62.42M
EBT excluding unusual items
-22.62M
-24.10M
-37.10M
-62.42M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-22.06M
-23.52M
-37.10M
-62.42M
Net profit margin
-
-
-
-
Earnings per share
-0.49
-0.51
-0.78
-1.29
Interest and investment income
3.18M
3.17M
3.84M
3.92M
Interest expense
-
-
-
-
Net interest expenses
3.18M
3.17M
3.84M
3.92M
Depreciation and amortization charges
-
-
-
-
EBITDA
-25.74M
-27.20M
-40.85M
-66.20M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps